Together, the companies would provide patients with true end-to-end neurological solutions using Brain Scientific’s diagnostic and motion technologies and IMAC’s regenerative rehabilitation medical services.
“We believe that the combination of IMAC and
IMAC is comprised of two business segments: outpatient medical centers and a clinical research division. IMAC owns or manages outpatient medical clinics that deliver regenerative rehabilitation services as a minimally invasive approach to acute and chronic musculoskeletal and neurological health problems. IMAC’s research division is currently conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinson’s disease.
“At Brain Scientific, we are accelerating the time to prep, test, and read EEG studies anytime and are finally bringing EEG testing to remote locations and in the field,” said
About IMAC Holdings, Inc.
IMAC Holdings owns and manages health and wellness centers that deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases. IMAC is comprised of two business segments: outpatient medical centers and a clinical research division. With treatments to address both young and aging populations, IMAC Holdings owns or manages outpatient medical clinics that deliver regenerative rehabilitation services as a minimally invasive approach to acute and chronic musculoskeletal and neurological health problems. IMAC’s research division is currently conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinson’s disease. For more information visit www.imacholdings.com.
About
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements, and terms such as “anticipate,” “expect,” “believe,” “may,” “will,” “should” or other comparable terms, are based largely on IMAC and BRSF's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC and BRSF's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to maintain and grow its business, the variability of its operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers’ requirements, and its ability to protect its intellectual property. Consummation of the merger transaction contemplated by the Letter of Intent is subject to the execution and delivery of a definitive merger agreement, the approval of each company's shareholders and the satisfaction of the closing conditions which will be contained therein. It is contemplated that the transaction will be consummated during the summer of 2023, but there can be no assurance that a definitive merger agreement will be entered into, or that the transaction will be consummated upon the terms set forth in the Letter of Intent, or otherwise. Additionally, there will be a number of risks attendant upon the transaction including unforeseen operating difficulties and expenditures during the process of integrating the companies. IMAC and BRSF encourage you to review other factors that may affect its future results in its public filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.
CONTACTS
IMAC Press Contact:
lfristoe@imacrc.com
Brain Scientific Contact:
INVESTORS
ir@brainscientific.com
MEDIA
pr@brainscientific.com
Corporate Communications
IBN (InvestorBrandNetwork)
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
![](https://ml.globenewswire.com/media/MTJmMzVkZWUtOTgzYS00ZTNmLTk5MzgtOWRhZTYwMDcyYTg2LTUwMDA3NTYzMg==/tiny/Brain-Scientific-Inc-.png)
2023 GlobeNewswire, Inc., source